Basilard BioTech is a biotechnology company developing next-generation nonviral gene delivery technologies designed to advance the engineering and manufacturing of cell and gene therapies. Our proprietary Celletto™ platform utilizes precision nanomechanical technology to deliver genetic material into cells while preserving cell viability and function.

Cell and gene therapies have the potential to transform the treatment of cancer, genetic disorders, and other serious diseases. However, conventional gene delivery methods, including viral vectors and electroporation, present significant challenges related to cell viability, delivery efficiency, payload flexibility, manufacturing complexity, and cost.

Celletto™ is designed to address these challenges through a proprietary silicon-based microelectromechanical (MEMS) platform that combines precision-engineered nanoneedles with controlled microfluidics. This approach enables nonviral delivery of genetic material into therapeutically relevant cell types, including T cells, NK cells, and induced pluripotent stem cells (iPSCs).

With encouraging early-stage performance data and a modular architecture designed for scalability, Basilard is advancing Celletto™ toward broader applications in cell therapy research, development, and manufacturing. Our mission is to enable more efficient, scalable, and accessible cell and gene therapies for patients worldwide.